Sullivan & Cromwell LLP advised Amgen, while Cooley LLP advised Five Prime. Skadden, Arps, Slate, Meagher & Flom LLP advised Lazard Frères & Co. LLC as financial advisor to Five Prime Therapeutics.
Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. This acquisition adds Five Prime’s innovative pipeline to Amgen’s leading oncology portfolio.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Goldman Sachs acted as financial advisor to Amgen. Lazard acted as financial advisor to Five Prime.
The Skadden team included M&A partners Graham Robinson (Boston; Picture) and Ann Beth Stebbins (New York), and associate Sydney Gaylin (Boston).
The Cooley team included Jamie Leigh, Ian Nussbaum, Laura Berezin, Jaime Chase, Polina Demina, Ty Carleton, Wendy Brenner, Natasha Leskovsek, Howard Morse, David Burns, Amanda Pacheco, Barbara Mirza and Kelsie Leigh Harris.
Involved fees earner: Laura Berezin – Cooley LLP; Wendy Brenner – Cooley LLP; David Burns – Cooley LLP; Ty Carleton – Cooley LLP; Jaime Chase – Cooley LLP; Polina Demina – Cooley LLP; Jamie Leigh – Cooley LLP; Kelsie Leigh Harris – Cooley LLP; Natasha Leskovsek – Cooley LLP; Barbara Mirza – Cooley LLP; Howard Morse – Cooley LLP; Ian Nussbaum – Cooley LLP; Amanda Pacheco – Cooley LLP; Sydney Gaylin – Skadden Arps Slate Meager & Flom; Graham Robinson – Skadden Arps Slate Meager & Flom; Ann Beth Stebbins – Skadden Arps Slate Meager & Flom;